|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hagleitner MM, Coenen MJ, Gelderblom H,
Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW,
Flucke U, van Leeuwen FN, et al: A first step toward personalized
medicine in osteosarcoma: Pharmacogenetics as predictive marker of
outcome after chemotherapy-based treatment. Clin Cancer Res.
21:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin JW, Squire JA and Zielenska M: The
genetics of osteosarcoma. Sarcoma. 2012:6272542012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: Emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye K, Wang S, Wang J, Han H, Ma B and Yang
Y: Zebularine enhances apoptosis of human osteosarcoma cells by
suppressing methylation of ARHI. Cancer Sci. 107:1851–1857. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lv YF, Yan GN, Meng G, Zhang X and Guo QN:
Enhancer of zeste homolog 2 silencing inhibits tumor growth and
lung metastasis in osteosarcoma. Sci Rep. 5:129992015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu MH, Fan MF and Yu XD: NSD2 promotes
osteosarcoma cell proliferation and metastasis by inhibiting
E-cadherin expression. Eur Rev Med Pharmacol Sci. 21:928–936.
2017.PubMed/NCBI
|
|
8
|
Liu Z, Piao L, Zhuang M, Qiu X, Xu X,
Zhang D, Liu M and Ren D: Silencing of histone methyltransferase
NSD3 reduces cell viability in osteosarcoma with induction of
apoptosis. Oncol Rep. 38:2796–2802. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu JH, Hubbell-Engler B, Adelmant G,
Huang J, Joyce CE, Vazquez F, Weir BA, Montgomery P, Tsherniak A,
Giacomelli AO, et al: PRMT1-mediated translation regulation is a
crucial vulnerability of cancer. Cancer Res. 77:4613–4625. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li S, Cheng D, Zhu B and Yang Q: The
overexpression of CARM1 promotes human osteosarcoma cell
proliferation through the pGSK3β/β-catenin/cyclinD1 signaling
pathway. Int J Biol Sci. 13:976–984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schuhmacher MK, Kudithipudi S, Kusevic D,
Weirich S and Jeltsch A: Activity and specificity of the human
SUV39H2 protein lysine methyltransferase. Biochim Biophys Acta.
1849:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang K, Mosch K, Fischle W and Grewal SI:
Roles of the Clr4 methyltransferase complex in nucleation,
spreading and maintenance of heterochromatin. Nat Struct Mol Biol.
15:381–388. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al-Sady B, Madhani HD and Narlikar GJ:
Division of labor between the chromodomains of HP1 and Suv39
methylase enables coordination of heterochromatin spread. Mol Cell.
51:80–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Carroll D, Scherthan H, Peters AH,
Opravil S, Haynes AR, Laible G, Rea S, Schmid M, Lebersorger A,
Jerratsch M, et al: Isolation and characterization of Suv39h2, a
second histone H3 methyltransferase gene that displays
testis-specific expression. Mol Cell Biol. 20:9423–9433. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bulut-Karslioglu A, De La Rosa-Velázquez
IA, Ramirez F, Barenboim M, Onishi-Seebacher M, Arand J, Galán C,
Winter GE, Engist B, Gerle B, et al: Suv39h-dependent H3K9me3 marks
intact retrotransposons and silences LINE elements in mouse
embryonic stem cells. Mol Cell. 55:277–290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peters AH, O'Carroll D, Scherthan H,
Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, Pagani M, Lachner
M, Kohlmaier A, et al: Loss of the Suv39h histone
methyltransferases impairs mammalian heterochromatin and genome
stability. Cell. 107:323–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
García-Cao M, O'Sullivan R, Peters AH,
Jenuwein T and Blasco MA: Epigenetic regulation of telomere length
in mammalian cells by the Suv39h1 and Suv39h2 histone
methyltransferases. Nat Genet. 36:94–99. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sone K, Piao L, Nakakido M, Ueda K,
Jenuwein T, Nakamura Y and Hamamoto R: Critical role of lysine 134
methylation on histone H2AX for γ-H2AX production and DNA repair.
Nat Commun. 5:56912014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mutonga M, Tamura K, Malnassy G, Fulton N,
de Albuquerque A, Hamamoto R, Stock W, Nakamura Y and Alachkar H:
Targeting suppressor of variegation 3–9 homologue 2 (SUV39H2) in
acute lymphoblastic leukemia (ALL). Transl Oncol. 8:368–375. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carvalho Alves-Silva J, do Amaral Rabello
D, Oliveira Bravo M, Lucena-Araujo A, Madureira de Oliveira D,
Morato de Oliveira F, Magalhaes Rego E, Pittella-Silva F and
Saldanha-Araujo F: Aberrant levels of SUV39H1 and SUV39H2
methyltransferase are associated with genomic instability in
chronic lymphocytic leukemia. Environ Mol Mutagen. 58:654–661.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braig M, Lee S, Loddenkemper C, Rudolph C,
Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T and
Schmitt CA: Oncogene-induced senescence as an initial barrier in
lymphoma development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Askew EB, Bai S, Parris AB, Minges JT and
Wilson EM: Androgen receptor regulation by histone
methyltransferase Suppressor of variegation 3–9 homolog 2 and
Melanoma antigen-A11. Mol Cell Endocrinol. 443:42–51. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Piao L, Suzuki T, Dohmae N, Nakamura Y and
Hamamoto R: SUV39H2 methylates and stabilizes LSD1 by inhibiting
polyubiquitination in human cancer cells. Oncotarget.
6:16939–16950. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Piao L, Nakakido M, Suzuki T, Dohmae N,
Nakamura Y and Hamamoto R: Automethylation of SUV39H2, an oncogenic
histone lysine methyltransferase, regulates its binding affinity to
substrate proteins. Oncotarget. 7:22846–22856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chi P, Allis CD and Wang GG: Covalent
histone modifications - miswritten, misinterpreted and mis-erased
in human cancers. Nat Rev Cancer. 10:457–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Greer EL and Shi Y: Histone methylation: A
dynamic mark in health, disease and inheritance. Nat Rev Genet.
13:343–357. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jacobsen LB, Calvin SA, Colvin KE and
Wright M: FuGENE 6 Transfection Reagent: The gentle power. Methods.
33:104–112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martin C and Zhang Y: The diverse
functions of histone lysine methylation. Nat Rev Mol Cell Biol.
6:838–849. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barski A, Cuddapah S, Cui K, Roh TY,
Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution
profiling of histone methylations in the human genome. Cell.
129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Biggar KK and Li SS: Non-histone protein
methylation as a regulator of cellular signalling and function. Nat
Rev Mol Cell Biol. 16:5–17. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamamoto R, Saloura V and Nakamura Y:
Critical roles of non-histone protein lysine methylation in human
tumorigenesis. Nat Rev Cancer. 15:110–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiong X, Zhang J, Liang W, Cao W, Qin S,
Dai L, Ye D and Liu Z: Fuse-binding protein 1 is a target of the
EZH2 inhibitor GSK343, in osteosarcoma cells. Int J Oncol.
49:623–628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bennani-Baiti IM, Machado I,
Llombart-Bosch A and Kovar H: Lysine-specific demethylase 1
(LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug
target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and
rhabdomyosarcoma. Hum Pathol. 43:1300–1307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dang-Nguyen TQ, Haraguchi S, Furusawa T,
Somfai T, Kaneda M, Watanabe S, Akagi S, Kikuchi K, Tajima A and
Nagai T: Downregulation of histone methyltransferase genes SUV39H1
and SUV39H2 increases telomere length in embryonic stem-like cells
and embryonic fibroblasts in pigs. J Reprod Dev. 59:27–32.
2013.PubMed/NCBI
|
|
37
|
Hunter RG, Murakami G, Dewell S, Seligsohn
M, Baker ME, Datson NA, McEwen BS and Pfaff DW: Acute stress and
hippocampal histone H3 lysine 9 trimethylation, a retrotransposon
silencing response. Proc Natl Acad Sci USA. 109:17657–17662. 2012.
View Article : Google Scholar : PubMed/NCBI
|
